Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
NCT00388037Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2007
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in ovarian epithelial cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC), sponsored by National Cancer Institute. Primary endpoint: Objective Response (Partial Response or Complete Response) as Per the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria up to 3 years. Started Jan 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00388037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00388037.